Volume 23, Issue 6, Pages (June 2016)

Slides:



Advertisements
Similar presentations
Camacho et al, Fig. S1 a c e b d f
Advertisements

Pratistha Ranjitkar, Amanda M. Brock, Dustin J. Maly 
Volume 14, Issue 5, Pages (May 2007)
Marissa V. Powers, Paul A. Clarke, Paul Workman  Cancer Cell 
De Novo Ceramide Synthesis Participates in the Ultraviolet B Irradiation-Induced Apoptosis in Undifferentiated Cultured Human Keratinocytes  Yoshikazu.
Volume 10, Issue 9, Pages (September 2003)
Volume 18, Issue 7, Pages (July 2011)
Marissa V. Powers, Paul A. Clarke, Paul Workman  Cancer Cell 
Volume 19, Issue 8, Pages (August 2012)
Volume 21, Issue 12, Pages (December 2014)
A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53
Volume 24, Issue 4, Pages e18 (April 2017)
Biofilm Inhibitors that Target Amyloid Proteins
Volume 19, Issue 7, Pages (July 2012)
AT-101, a Pan-Bcl-2 Inhibitor, Leads to Radiosensitization of Non-small Cell Lung Cancer  Luigi Moretti, MD, Bo Li, MD, Kwang Woon Kim, PhD, Heidi Chen,
Volume 22, Issue 3, Pages (March 2015)
Volume 19, Issue 9, Pages (September 2012)
Volume 24, Issue 8, Pages e7 (August 2017)
Volume 24, Issue 11, Pages e4 (November 2017)
Volume 19, Issue 4, Pages (April 2012)
Volume 19, Issue 4, Pages (April 2012)
Volume 16, Issue 4, Pages (April 2009)
Volume 12, Issue 1, Pages (January 2005)
Volume 18, Issue 11, Pages (November 2011)
Volume 19, Issue 6, Pages (June 2012)
Ai-Sun Tseng, Felix B. Engel, Mark T. Keating  Chemistry & Biology 
Fluorogenic Probe for Constitutive Cellular Endocytosis
Volume 17, Issue 1, Pages (January 2010)
Volume 25, Issue 3, Pages e3 (March 2018)
Volume 19, Issue 12, Pages (December 2012)
Volume 22, Issue 6, Pages (June 2015)
Volume 23, Issue 2, Pages (February 2016)
Volume 19, Issue 7, Pages (July 2012)
Identification of Small Molecule Inhibitors that Distinguish between Non-Transferrin Bound Iron Uptake and Transferrin-Mediated Iron Transport  Jing Xu.
Volume 23, Issue 4, Pages (April 2016)
Stable and Potent Selenomab-Drug Conjugates
Volume 18, Issue 6, Pages (June 2011)
Volume 22, Issue 2, Pages (February 2015)
Volume 20, Issue 9, Pages (September 2013)
Volume 24, Issue 8, Pages e4 (August 2017)
Jae Won Chang, Daniel K. Nomura, Benjamin F. Cravatt 
Volume 24, Issue 12, Pages e5 (December 2017)
Volume 24, Issue 11, Pages e8 (November 2017)
Volume 19, Issue 9, Pages (September 2012)
Volume 21, Issue 11, Pages (November 2014)
Volume 16, Issue 12, Pages (June 2006)
Volume 16, Issue 6, Pages (June 2009)
Volume 19, Issue 1, Pages (April 2017)
An Electrophoretic Mobility Shift Assay Identifies a Mechanistically Unique Inhibitor of Protein Sumoylation  Yeong Sang Kim, Katelyn Nagy, Samantha Keyser,
Volume 16, Issue 6, Pages (June 2009)
Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance  Valeria R. Fantin, Julie St-Pierre,
Volume 24, Issue 2, Pages (February 2017)
Volume 13, Issue 4, Pages (April 2006)
Volume 20, Issue 11, Pages (November 2013)
The Membrane-Lytic Peptides K8L9 and Melittin Enter Cancer Cells via Receptor Endocytosis following Subcytotoxic Exposure  Masayuki Kohno, Tomohisa Horibe,
Volume 24, Issue 7, Pages e6 (July 2017)
Very Long Chain Fatty Acids Are Functionally Involved in Necroptosis
Volume 18, Issue 5, Pages (May 2011)
Volume 17, Issue 6, Pages (June 2010)
Volume 22, Issue 11, Pages (November 2015)
Pratistha Ranjitkar, Amanda M. Brock, Dustin J. Maly 
Volume 12, Issue 6, Pages (June 2005)
Volume 19, Issue 1, Pages (April 2017)
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia  Raquel Vinhas, Alexandra R.
Volume 18, Issue 11, Pages (November 2011)
Molecular Therapy - Nucleic Acids
Volume 17, Issue 8, Pages (August 2010)
Gemcitabine-Incorporated G-Quadruplex Aptamer for Targeted Drug Delivery into Pancreas Cancer  Jun Young Park, Ye Lim Cho, Ju Ri Chae, Sung Hwan Moon,
Volume 22, Issue 12, Pages (December 2015)
Presentation transcript:

Volume 23, Issue 6, Pages 678-688 (June 2016) Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity in the MMTV-Neu Model of HER2+ Breast Cancer  Yazan Alwarawrah, Philip Hughes, David Loiselle, David A. Carlson, David B. Darr, Jamie L. Jordan, Jessie Xiong, Lucas M. Hunter, Laura G. Dubois, J. Will Thompson, Manjusha M. Kulkarni, Annette N. Ratcliff, Jesse J. Kwiek, Timothy A.J. Haystead  Cell Chemical Biology  Volume 23, Issue 6, Pages 678-688 (June 2016) DOI: 10.1016/j.chembiol.2016.04.011 Copyright © 2016 Elsevier Ltd Terms and Conditions

Cell Chemical Biology 2016 23, 678-688DOI: (10. 1016/j. chembiol. 2016 Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 1 Discovery of the FASN Inhibitor Fasnall (A) Cibacron blue Sepharose was incubated with porcine lactating mammary gland extracts (a rich source of FASN), washed, and the bound proteins labeled with fluorescein. A small-molecule library of druggable molecules with structural similarity to any purine or known purine analog scaffold was assembled and tested for the ability of each molecule to compete fluorescein-labeled proteins off Cibacron blue resin, proteins from the eluents that had high fluorescence intensity were separated by SDS-PAGE and silver stained, then proteins were identified by MS. (B) The screen of 3,379 purine-based compounds identified 247 hits with high fluorescent signal. Of the 247 hits, 155 were selected by virtue of both a high FASN intensity and a low number of non-FASN protein bands. The 20 most selective compounds were tested for anti-FASN activity in a [3H]glucose incorporation assay (Figure S1) and the molecule with the highest activity (Fasnall) was selected as a lead molecule. Cell Chemical Biology 2016 23, 678-688DOI: (10.1016/j.chembiol.2016.04.011) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 2 In Vitro Activity of Fasnall and Its Enantiomers (A) HS molecules inhibit both tritiated acetate (IC50 147 nM) and glucose (IC50 213 nM) incorporation into lipids. (B) Fasnall inhibits the human purified FASN activity of [14C]malonyl-CoA incorporation into lipids with an IC50 of 3.71 μM. (C) Structures of Fasnall enantiomers and the truncated molecule HS-102. (D) Both Fasnall enantiomers were able to inhibit the incorporation of tritiated acetate (IC50 5.84 μM, 1.57 μM, and 7.13 μM for Fasnall, HS-79, and HS-80, respectively) into lipids in BT474 cells while the truncated molecule HS-102 had no significant effect on acetate incorporation into lipids (mean ± SEM). Cell Chemical Biology 2016 23, 678-688DOI: (10.1016/j.chembiol.2016.04.011) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 3 Selectivity of Fasnall Individual compounds were assayed for their ability to elute proteins from Cibacron blue resin. Blue-red color spectrum indicates protein concentration as measured by fluorescence (see FLECS Methods). SDS-PAGE and MS analysis showed that Fasnall selectively elutes FASN compared with strong (HS-206160) and weak (HS-202889) hits. Bottom (red graph): compound library was screened for inhibitory activity against the following enzymes: ACC, ZipK, AMPKα, AMPKγ, TRAP1, HSP70, NS5, and IRAK2; Fasnall was a potent inhibitor of FASN (only). Cell Chemical Biology 2016 23, 678-688DOI: (10.1016/j.chembiol.2016.04.011) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 4 Anti-proliferative Activity of Fasnall (A–E) Based on the DNA content measured by staining with Hoechst, treating various types of breast cancer cell lines with one dose of 50 μM Fasnall (closed circles) was able to inhibit cell proliferation with potency similar to 50 μM C75 (open triangles) except for the non-tumorigenic cell line MCF10A when compared with control (closed squares). (F) Cell-cycle analysis for BT474 cells treated with different concentrations of Fasnall for 24 hr shows an increase in the Sub 2N population (mean ± SEM). (G) Treating breast cancer cell lines with 10 μM Fasnall for 24 hr did not have any effect on the expression of FASN. Cell Chemical Biology 2016 23, 678-688DOI: (10.1016/j.chembiol.2016.04.011) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 5 Fasnall Effects on the Lipidome BT474 cells were treated with 10 μM Fasnall for 2 hr, then lipids were extracted and subjected to LC-MS. More than 3,000 lipid features were quantified using both ESI+ and ESI− analyses. (A) Each point represents one of the lipid molecules that were quantified, aggregated for ESI+ and ESI−. The color of each dot represents extent of significant difference in the abundance between the control and treatment according to the scale shown on the right. (B) Of the lipids that were identified, many were diacylglycerols. Ceramides and fatty acids were found to increase over the control (*p < 0.01, #p < 0.05, n = 5) (mean ± SEM). (C) BT474 cells were treated with different concentrations of Fasnall for 1 hr and lipids were separated by aminopropyl cartridges after incubating the cells with [3H]acetate for 2 hr. Fasnall was able to inhibit the incorporation of acetate into the different types of lipids, especially the more abundant phospholipids. A similar experiment was done with [14C]palmitate, which showed a dose-dependent increase in palmitate sequestering into free fatty acids and reduction in its incorporation into phospholipids. Similar to free fatty acids, neutral lipids increased except for at 50 μM Fasnall, when they decreased (mean ± SEM). (D) Treatment of BT474 cells with different concentrations of Fasnall under 10% FBS conditions induce the formation of lipid droplets as shown by oil red O staining, indicating an increase in neutral lipids formation when compared with 1% FBS. Cell Chemical Biology 2016 23, 678-688DOI: (10.1016/j.chembiol.2016.04.011) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 6 Fasnall Induces Apoptosis in HER2+ Breast Cancer Cells (A) The indicated cells were treated with different concentrations of Fasnall or C75 for 24 hr, then caspase-3/-7 activity was assayed using the fluorogenic substrate (DEVD)2-r110. (B) The same experiment was repeated for longer treatment time (48 hr), further showing that Fasnall has more selective induction of apoptosis in the HER2+ cell lines when compared with C75. (C) Cells were pretreated for 1 hr with 100 μM of a mixture of 1:2 palmitate/oleate in complex with 0.1% BSA (FA) or 15 μM TOFA, or both (TOFA + FA). All the treatments contained the exact amount of BSA and DMSO. Cells were then treated with different concentrations of Fasnall or C75 for 24 hr, and caspase-3/-7 activity was assayed (mean ± SEM). Cell Chemical Biology 2016 23, 678-688DOI: (10.1016/j.chembiol.2016.04.011) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 7 Fasnall Activity in MMTV-Neu Mice (A) Fasnall does not induce weight change. Mice were assessed weekly, treated twice weekly with an intraperitoneal injection of different concentrations of Fasnall made in DMSO/saline (1:1) (mean ± SEM). (B and C) Combination of Fasnall and carboplatin (Carbo) significantly reduces tumor volume (t test, p = 0.014). (D) Fasnall increases the median survival of mice from 29 to 63 days, with a log-rank p value of 0.049. biw, twice weekly; qw, weekly. Cell Chemical Biology 2016 23, 678-688DOI: (10.1016/j.chembiol.2016.04.011) Copyright © 2016 Elsevier Ltd Terms and Conditions